Author

Belén Ferro

Institution: UCB Pharma (Spain)

Observed institution: UCB Pharma (Spain)

OpenAlex ID: A5111754366

Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain

2015 · Álvaro Hidalgo-Vega, Renata Villoro, et al. · Cost Effectiveness and Resource Allocation · 11

Tratamiento biológico de la artritis reumatoide en España. Análisis de impacto presupuestario de la utilización de certolizumab pegol

2013 · Álvaro Hidalgo, Renata Villoro, et al. · PharmacoEconomics Spanish Research Articles · 1

Works count: 2

Citation count: 12

H-index: 1

I10-index: 1